Monthly Archives: January, 2026

Kazia Therapeutics announces compelling preclinical and translational data for nuclear PD-L1 degrader (NDL2)

Julian English - 31 January 2026

Kazia Therapeutics, an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, has announced compelling preclinical and translational data supporting the development of NDL2,...

Mammoth Biosciences announces new results on NanoCas – the first efficient ultracompact extrahepatic gene editor

EditorJ - 8 January 2026

Mammoth Biosciences, a biotechnology company harnessing its proprietary next-generation CRISPR gene editing platform to create potential one-time curative therapies, today announced new preclinical research,...

Orexo announces positive outcome from in vivo study of OX390

19 June 2026

MEKanistic Therapeutics announces FDA clearance of IND for MTX-531, enabling phase 1 trials in advanced solid tumours

19 June 2026

Matter Bio files first IND for Lm-LLO-TT, advancing first-in-human phase 1/2a study in patients with pancreatic cancer

19 June 2026

Myosin Therapeutics initiates phase 1/2 trial of MT-125 targeting non-muscle myosin II in newly diagnosed glioblastoma

19 June 2026

Drug Discovery & Development (DDD) is dedicated to advancing scientific innovations into active medical solutions. Its aim is to accelerate breakthroughs in medicine, addressing human disease and improving global health outcomes.

Orexo announces positive outcome from in vivo study of OX390

MEKanistic Therapeutics announces FDA clearance of IND for MTX-531, enabling phase 1 trials in advanced solid tumours

Matter Bio files first IND for Lm-LLO-TT, advancing first-in-human phase 1/2a study in patients with pancreatic cancer

Myosin Therapeutics initiates phase 1/2 trial of MT-125 targeting non-muscle myosin II in newly diagnosed glioblastoma

New clinical study shows pasteurised Akkermansia muciniphila MucT supports weight loss maintenance

Monthly Archives: January, 2026

Most Read

Orexo announces positive outcome from in vivo study of OX390

MEKanistic Therapeutics announces FDA clearance of IND for MTX-531, enabling phase 1 trials in advanced solid tumours

Matter Bio files first IND for Lm-LLO-TT, advancing first-in-human phase 1/2a study in patients with pancreatic cancer

Myosin Therapeutics initiates phase 1/2 trial of MT-125 targeting non-muscle myosin II in newly diagnosed glioblastoma

Menu